title: Kisspeptin effect on endothelial monocyte activating polypeptide II (EMAP-II)-associated lymphocyte cell death and metastases in colorectal cancer patients.
abstract: Kisspeptin is an antimetastatic agent in some cancers that has also been associated with lymphoid cell apoptosis, a phenomenon favoring metastases. Our aim was to determine the association of kisspeptin with lymphocyte apoptosis and the presence of metastases in colorectal cancer patients. Blood was drawn from 69 colon cancer patients and 20 healthy volunteers. Tissue specimens from healthy and pathological tissue were immunohistochemically analyzed for kisspeptin and endothelial monocyte activating polypeptide II (EMAP-II) expression. Blood EMAP-II and soluble Fas ligand (sFasL) levels were examined by an enzyme-linked immunosorbent assay method. The kisspeptin and EMAP-II expression and secretion levels in the DLD-1 and HT-29 colon cancer cell lines were examined by quantitative real-time polymerase chain reaction, Western analysis and enzyme-linked immunosorbent assay, whereas lymphocyte viability was assessed by flow cytometry. The effect of kisspeptin on the viability of colon cancer cells was examined by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. Exogenous, synthetic and naturally produced, kisspeptin induces through the G-protein-coupled receptor 54 (GPR54; also known as the kisspeptin receptor) the EMAP-II expression and secretion in colon cancer cell lines, inducing in vitro lymphocyte apoptosis, as verified by the use of an anti-EMAP-II antibody. These results were reversed with the use of kisspeptin inhibitors and by kisspeptin-silencing experiments. Tumor kisspeptin expression was associated with the tumor EMAP-II expression (p < 0.001). Elevated kisspeptin and EMAP-II expression in colon cancer tissues was associated with lack of metastases (p < 0.001) in colon cancer patients. These data indicate the antimetastatic effect of tumor-elevated kisspeptin in colon cancer patients that may be mediated by the effect of kisspeptin on EMAP-II expression in colon cancer tumors in patients with normal serum EMAP-II levels. These findings provide new insight into the role of kisspeptin in the context of metastases in colon cancer patients.
authors.affiliation: First Propadeutic Surgical Clinic, Athens Medical School, National and Kapodestrian University of Athens, Athens, Greece Physiology Laboratory, Athens Medical School, National and Kapodestrian University of Athens, Athens, Greece.
authors.forename: Martha
authors.initials: M
authors.lastname: Stathaki
authors.affiliation: Physiology Laboratory, Athens Medical School, National and Kapodestrian University of Athens, Athens, Greece.
authors.forename: Athanasios
authors.initials: A
authors.lastname: Armakolas
authors.affiliation: Physiology Laboratory, Athens Medical School, National and Kapodestrian University of Athens, Athens, Greece.
authors.forename: Andreas
authors.initials: A
authors.lastname: Dimakakos
authors.affiliation: Department of Pathology, Onasio Hospital, Athens, Greece.
authors.forename: Loukas
authors.initials: L
authors.lastname: Kaklamanis
authors.affiliation: Physiology Laboratory, Athens Medical School, National and Kapodestrian University of Athens, Athens, Greece.
authors.forename: Ioannis
authors.initials: I
authors.lastname: Vlachos
authors.affiliation: First Propadeutic Surgical Clinic, Athens Medical School, National and Kapodestrian University of Athens, Athens, Greece.
authors.forename: Manoussos M
authors.initials: MM
authors.lastname: Konstantoulakis
authors.affiliation: First Propadeutic Surgical Clinic, Athens Medical School, National and Kapodestrian University of Athens, Athens, Greece.
authors.forename: George
authors.initials: G
authors.lastname: Zografos
authors.affiliation: Physiology Laboratory, Athens Medical School, National and Kapodestrian University of Athens, Athens, Greece.
authors.forename: Michael
authors.initials: M
authors.lastname: Koutsilieris
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000473:pathology; D016207:Cytokines / Q000097:blood / Q000378:metabolism*; D020868:Gene Silencing; D006801:Humans; D059648:Kisspeptins / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000097:blood / Q000378:metabolism*; D016601:RNA-Binding Proteins / Q000097:blood / Q000378:metabolism*; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors / Q000378:metabolism; D000074502:Receptors, Kisspeptin-1
chemical_list: D016207:Cytokines; C106628:KISS1 protein, human; C118688:KISS1R protein, human; D059648:Kisspeptins; D009363:Neoplasm Proteins; D016601:RNA-Binding Proteins; D043562:Receptors, G-Protein-Coupled; D000074502:Receptors, Kisspeptin-1; C077219:small inducible cytokine subfamily E, member 1